Jun
21
2022

Super Trial

By OVG

A Phase 2b, Multi-Center, Placebo-Controlled, Randomized Study of BPZE1 Intranasal Pertussis Vaccine in Healthy School-Age Children to Assess the Immunological Response and Safety Profile of a Single Dose BPZE1 With and Without Co-Administration of Tetanus, Diphtheria, and Acellular Pertussis (Boostrix™)

 

This is an international study enrolling 600 children/teenagers aged 6 to 17 years old and is being funded by a company called ILiAD Biotechnologies.

Nov
24
2021

MENACWY = MEN7B-003

By OVG

MenABCWY=Men7B-003 : A Phase II, randomised, partially blinded study to assess the safety, tolerability, and immunogenicity of meningococcal combined ABCWY vaccine when administered to healthy infants.

Short Title: Combining vaccines against meningitis: An infant immunisation study

Oxford Vaccine Group would like to invite your baby to participate in a study looking at a new combined Meningitis vaccine, designed to allow us to give babies protection against many different strains of meningitis using fewer injections.

Jul
09
2018

POInT

By OVG

The Oxford Vaccine Group is recruiting infants aged 4 – 7 months to a type 1 diabetes prevention trial. POInT (Primary Oral Insulin Trial) is recruiting infants who were screened for diabetes at birth through the INGR1D Study and have been found to be at high risk for developing diabetes.

Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, University of Oxford, OX3 7LE.

This unit receives National Institute for Health Research CTU Support Funding. This funding has been awarded to support the unit in developing and supporting NIHR trials.